Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 330
- 试验地点
- 1
- 主要终点
- compare mortality
研究概览
简要总结
Hypomagnesemia is a common entity in the inpatient and outpatient setting. in previous retrospective study hypomagnesemic patients have higher mortality and longer hospitalization. whether hypomagnesemia is merely a marker of poor prognosis, or whether replacing it can improve outcomes is unclear. The current standard of care is to discharge these patients without workup or further treatment, even if patients had received intravenous therapy while hospitalized. The investigator wish to examine prospectively whether giving replacement therapy affects mortality, length of hospital stay and overall well-being. In order to replete intracellular levels and replete magnesium stores, magnesium should be given for several months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Any patient admitted over the age of 18, has hypomagnesemia (magnesium level ≤1.9 mg/dL) and is able to give consent.
排除标准
- •A patient unable to give consent.
- •A patient admitted for an elective procedure.
- •A patient in critical condition or dying.
- •Patients with advanced kidney disease with eGFR<15ml/min or on dialysis.
- •Patients with severe diarrhea, precluding use of magnesium citrate.
- •Patients already receiving magnesium supplements.
- •Patients with severe malnutrition or life-threatening hypomagnesemia (serum level <1mg/dL), requiring intravenous and oral replacement of magnesium.
研究组 & 干预措施
Experimental group
After initial intravenous treatment, participants (those with magnesium level ≥1 mg/dL) will be randomized, and oral magnesium therapy ( or no treatment) will be started. The experimental group will receive 400mg magnesium daily in two divided doses. Patients in the experimental group will be discharged with one month's supply of magnesium and continued for at least three months.
干预措施: Magnesium Citrate 100 MG (Drug)
结局指标
主要结局
compare mortality
时间窗: one year
To compare mortality between the population receiving magnesium and the population receiving standard care: ie no replacement.
次要结局
- Hospitalization(one year)
研究者
Frieda Wolf
Senior Physician in Internal Medicine C, Haemek Medical Center, Israel
HaEmek Medical Center, Israel